Detection of JAK2V617F mutation and its clinical significance in 80 patients with M2 acute myelogenous leukemia.
- Author:
Yi-min SHEN
1
;
Hong-ying CHAO
;
Ri ZHANG
;
Wei-yang LI
;
Yu-feng FENG
;
Zi-ling ZHU
;
Yong-quan XUE
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; DNA Mutational Analysis; DNA, Neoplasm; genetics; Female; Follow-Up Studies; Humans; Janus Kinase 2; genetics; Leukemia, Myeloid, Acute; drug therapy; genetics; Male; Middle Aged; Mutation; Remission Induction; Survival Rate; Young Adult
- From: Chinese Journal of Oncology 2009;31(5):366-370
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the prevalence and prognostic significance of JAK2V617F gene mutation in acute myelogenous leukemia M2 (AML-M2) patients.
METHODSAllele specific polymerase chain reaction (PCR) was used to detect JAK2 gene mutation.
RESULTSOf 80 de novo AML-M2 patients, 6 at the time of first diagnosis and 1 at relapse were found to have JAK2V617F gene mutation (8.8%, 7/80). Morphologically, the whole blood and bone marrow of the 7 AML-M2 patients with JAK2V617F gene mutation presented a picture of acute leukemia instead of myeloproliferative disorders. Immunophenotypically, bone marrow samples showed myelogenous linage expression. Complete remission was obtained in 4 of 5 AML-M2 patients with JAK2V617F mutation who received treatment, while one patient had no response to the treatment. Follow-up was performed in all the 5 patients, with a median survival of 18.5 months in 4 patients.
CONCLUSIONJAK2V617F gene mutation, as a type-1 mutation, might not be an initial event in the pathogenesis of acute myelogenous leukemia, and its presentation does not mean a poor prognosis in de novo AML patients.
